Spironolactone metabolite concentrations in decompensated heart failure: Insights from the ATHENA-HF trial.

BACKGROUND. In Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy in Heart Failure (ATHENA-HF), high-dose spironolactone (100 mg daily) did not improve efficacy endpoints over usual care (placebo or continued low-dose spironolactone [25 mg daily] in patients already receiving spiro...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur J Heart Fail
Autores principales: de Denus, Simon, Leclair, Grégoire, Dubé, Marie-Pierre, St-Jean, Isabelle, Zada, Yassamin Feroz, Oussaïd, Essaïd, Jutras, Martin, Givertz, Michael M., Mentz, Robert J., Tang, W. H. Wilson, Ferreira, João P, Rouleau, Jean, Butler, Javed, Kalogeropoulos, Andreas P.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7958586/
https://ncbi.nlm.nih.gov/pubmed/32237012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1802
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares